Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

BACKGROUND: Large trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of adverse kidney and cardiovascular outcomes in patients with heart failure or chronic kidney disease, or with type 2 diabetes and high risk of atherosclerotic cardiovascular disease. INTERPRETATION: In addition to the established cardiovascular benefits of SGLT2 inhibitors, the randomised data support their use for modifying risk of kidney disease progression and acute kidney injury, not...

⚡ This is an original paraphrased summary — not copied from the abstract. Full paper available at the source link below.

• 1 None of the trials recruiting patients with and without diabetes were designed to assess outcomes separately in patients without diabetes.
• 2 METHODS: We did a systematic review and meta-analysis of SGLT2 inhibitor trials.
• 3 We searched the MEDLINE and Embase databases for trials published from database inception to Sept 5, 2022.

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

This summary is based on publicly available metadata and abstract. For the full research paper, visit the original source: